Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
AMLX Weekly Chart

Old Forum Content for AMLX

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • woodman: $AMLX #Biotech - no position in this one, but it's a reminder for biotech investors what can happen with major binary events. This one had an ALS confirmatory trial fail. Down 83% now. Anyone who has invested in smid biotechs for a while has felt this kind of burn. Position size is crucial going into major binary events.
  • woodman: $AMLX #Biotech $EFTR - So, if you are in $EFTR, make sure you are comfortable with your position size if holding through coming data in case the data are bad.
  • woodman: $AMLX $EFTR #Biotech - One more note about EFTR - remember that after the lung cancer data expected this month, it will report additional data for its beast cancer trial expected first half of this year.
  • woodman: @wjj3 $EFTR - today's action is irrelevant. Today, people are making choices before the binary event of data for lung cancer due this month. The data update is what will matter ultimately. Moves in the stock today are meaningless. It's a very tiny market cap stock. It can be pushed around easily. And the failure of $AMLX probably has spooked mamy retail holders.
  • sierramp: @woodman $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR #Biotech Thank you for this. Can't buy them using my usual process for evaluation but very, very interesting so attempting to come up with another way to evaluate. If you have time, would you share how they pass your test?
  • woodman: @sierramp $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR #Biotech - Catalysts (trial data due; FDA decisions due, etc.), important therapeutic areas and potential moats, interesting combos with established companies and institutions, strong interest by people I respect. Not all of these necessarily apply to each and every one, but some of these elements apply to each. Not an exhaustive list, but what instantly came to mind. Fwiw, I provided a small bit of color on most of these in a prior recent post here that you can search for. The chart is a factor, but to a more limited extent - less so than my ordinary trading MO.
  • pperlroth: @woodman $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR #Biotech These are great! Thank you for sharing as I often look to this industry as the payouts can be massive given potential takeovers AND potential FDA approvals for new drugs/therapies.
  • woodman: Updated list of #Biotech that I'm currently in ($$ amounts vary; not in any particular order): $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR (bought today).
  • woodman: Current #biotech and Big #Pharma that I'm in: $ARDX (gift drop 2 days ago; catalyst with news likely in January - see my prior posts) $CPRX (keeps going) $ORMP (strong today; catalyst into January for P3 results for oral insulin; also, CEO just talke ...
  • woodman: $AMLX bounce off rising 50d.
  • woodman: $AMLX trying to breakout again. Still unable, but I think should be watched. This one recently got its first therapy approval (for ALS) in late Sept. It has other neurodegenerative disease therapies in the pipeline.
  • woodman: $AMLX - this biotech focusing on neurodegenerative diseases (read about its approvals and pipeline here: https://www.amylyx.com/pipeline ) will be presenting at this health conference on 11/29. https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-participate-evercore-isi-5th-annual On the chart, it's squeezing on the 50d. Perhaps the conference will be a catalyst for a move higher.
  • issues: @mharps $BMRN Thank you for mentioning this one. I also bought it and $MRNA. I put in a limit order on $AMLX. Also we own $VRTX which reports tonight AH . All these are in the IBD group 10 Biomed. Good group to be in.
Visit the Trading Forum to join in the discussion.
Stock Price $6.24
Change -11.24%
Volume 2,003,390

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.

Request Video of AMLX
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!